Hydrogen water reduces NSE, IL-6, and TNF-α levels in hypoxic-ischemic encephalopathy
Yang L, Li D, Chen S. · Open medicine (Warsaw, Poland). 2016;11(1):399-406.
What kind of evidence is this?
Human
Human interventional or observational study
Cancer research
H₂-rich water
Not reported in this record.
Not reported in this record.
Methods at a glance
Human participants studied for cancer research. See eligibility criteria in the linked full text.
Human study; group or assay counts reported in the full text include n=20.
10 days
Full text reports H₂ dissolved in drinking water. Detected intervention quantities or schedules: 0.9%, 0.6 mmol/L, 10 days, 5 mL/kg, 3 mL.
H₂ dissolved in drinking water — H₂ only unless the full text explicitly reports oxygen co-delivery.
H₂-related quantities reported in the intervention passages: 0.9%, 0.6 mmol/L, 10 days, 5 mL/kg, 3 mL. Values are not combined across different experimental arms.
Not applicable — no inhaled H₂ intervention was identified in the full article.
No inhaled O₂ co-delivery was identified for this non-inhalation intervention.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury
Article-reported result excerpt (24 words maximum): “Anterior fontanel tension, disturbance of consciousness, muscle tone, primitive reflex recovery time, and con-vulsion control time were significantly decreased in the hydrogen water treatment…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Human evidence; design, sample size and comparator limit interpretation. No funding statement was identified in the machine-readable full article; absence is not inferred. No explicit conflict statement was identified in the machine-readable full article; absence is not inferred.
Applies only to the population and protocol reported in this cancer research article.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 28352827 · DOI: 10.1515/med-2016-0072
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10